Novartis takes on Regeneron, Roche blockbusters with Beovu approval
Look out, Regeneron and Roche. Novartis has the FDA go-ahead for its next blockbuster launch in Beovu, a drug for wet age-related macular degeneration (AMD) that beat out Regeneron's big-selling Eylea on some measures in a head-to-head trial.
Novartis' Beovu won FDA approval Tuesday to treat wet AMD, a condition expected to affect 1.75 million people in the U.S. next year.
In addition to Eylea, the med threatens Roche's Lucentis, which Novartis itself markets in Europe. That drug loses European patent protection in 2020, so Novartis expects to launch Beovu in Europe as Lucentis faces copycats there.